论文部分内容阅读
To assess the safety and feasibility of percutaneous cryoablation on pancreatic cancer via ultrasonography (US) and computed tomography (CT) guidance.Materials and methods: This retrospective review was approved by the institutional review board and of informed consent.Thirty two patients (18 men and 14 women; median age 62; age rang,30-77years) with pancreatic cancer (stage II/III/IV,3/11/18) treated with percutaneous US and CT guided cryoablations between February 2009 to February 2010 were eligible for this review.Thirteen tumors in pancreatic head and 19 in pancreatic body and/or tail measuring 2-11 cm (mean,5.2 cm ± 8 [standard deviation]) were ablated with 49 procedures in total.Feasibility was analyzed by enhanced CT 1-3 months post procedure and safety was assessed by clinical signs,symptoms and laboratory results.Results: Neither procedural death nor serious complications occurred.Fifteen tumors (46.9%) smaller than 5 cm were successfully ablated by one session of cryoablation.Twenty-seven patients experienced a ≥50% reduction in pain score,22 experienced a 50% decrease in analgesic consumption and 16 experienced an ≥20 increase in Karnofsky Performance Status (KPS) Score.Partial response (PR) and stable disease (SD) turned up in 9 and 21 patients,respectively,lesions in whom were identified controlled by none enhancement on enhanced CT.Mean and median survival was 15.9 and 12.6 months,respectively.The 6 -,12- and 24- month survival rates were 82.8%,54.7% and 27.3%,respectively.Conclusion: US and CT guided percutaneous cryoablation is a safe and promising local treatment for pancreatic cancer.